The landscape of metabolic disease treatment has been dramatically reshaped in recent years by the advent of glucagon-like peptide-1 (GLP-1) receptor agonists, medications that have proven instrumental in managing conditions such as obesity, type 2 diabetes, and non-alcoholic fatty liver disease. Widely recognized under brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, these pharmaceuticals facilitate significant weight reduction and contribute to improved glycemic control. However, their therapeutic benefits are not without potential drawbacks. A subset of individuals using these medications report experiencing adverse effects, most notably nausea and other gastrointestinal disturbances. Moreover, the appetite-suppressing nature of GLP-1 drugs, while central to their weight loss efficacy, can lead to reduced caloric and nutrient intake, potentially resulting in nutritional deficiencies and a decrease in muscle mass. This loss of lean tissue raises concerns about increased frailty and other long-term health complications for some patients.
In response to these limitations and seeking alternative therapeutic avenues, a research team at the University of California, Berkeley, has embarked on an investigation into a fundamentally different approach to tackling obesity and metabolic dysfunction. Rather than focusing on reducing energy intake, their strategy aims to augment the body’s energy expenditure by elevating its inherent metabolic rate. This innovative direction seeks to shift the paradigm from calorie restriction to calorie combustion.
The scientific community has been presented with the findings of this groundbreaking research, detailed in a study published on August 21st in the journal Science Advances. The focal point of this investigation is a specific molecular compound, identified as 5-tetradecyloxy-2-furoic acid, or TOFA. This compound exhibits a dual-action mechanism: it actively interferes with the biochemical pathways responsible for synthesizing lipids, including cholesterol and triglycerides, while simultaneously activating a suite of genes that promote the utilization of stored fat as an energy source, thereby boosting overall cellular energy production.
In preclinical trials conducted with rodent models, TOFA demonstrated a remarkable capacity to enhance insulin sensitivity and improve glucose regulation. Concurrently, it led to a reduction in triglyceride levels and ameliorated key indicators of fatty liver disease. Crucially, obese mice treated with TOFA experienced a notable decrease in body fat mass without any discernible loss of lean muscle tissue. This preservation of muscle mass represents a significant departure from some existing weight-loss interventions, which can inadvertently lead to sarcopenia.
Professor Anders Nørgaard, a leading expert in metabolic biology and nutrition at UC Berkeley and the senior author of the study, articulated the core principle guiding their research. He explained that body weight is influenced by two primary physiological levers: caloric intake and energy expenditure. While GLP-1 medications predominantly operate on the former by curbing appetite, the Berkeley team deliberately targeted the latter, seeking to increase the body’s "energy spending" capacity.
The journey of TOFA within the scientific realm began decades ago, with its initial discovery tracing back to the 1970s. It belongs to a class of compounds known as ACC (acetyl-CoA carboxylase) inhibitors. These inhibitors function by impeding the body’s endogenous production of lipids. The therapeutic potential of ACC inhibitors has been recognized for some time, with several compounds from this group progressing to mid-stage clinical evaluations. However, none have yet secured regulatory approval for the treatment of metabolic disorders. A significant hurdle that has historically impeded the development of many ACC inhibitors is their propensity to elevate triglyceride levels, a factor that can heighten the risk of cardiovascular complications.
The UC Berkeley research team’s critical insight lies in TOFA’s distinct pharmacological profile. Beyond its capacity as an ACC inhibitor, TOFA demonstrates an ability to activate specific cellular receptors, namely PPARα (peroxisome proliferator-activated receptor alpha) and PPARγ (peroxisome proliferator-activated receptor gamma). These receptors act as key regulators, initiating the expression of genes that are integral to the uptake and subsequent metabolic breakdown of fatty acids for energy generation.
In the animal studies, this multifaceted activation by TOFA resulted in an observable increase in energy expenditure, reaching up to 18%. Intriguingly, this metabolic boost did not correlate with increased physical activity levels in the animals, nor did it lead to an elevation in their core body temperature. Furthermore, a key finding was that TOFA did not induce the problematic rise in triglyceride levels that has been a concern with other ACC inhibitors. The researchers posit that this favorable outcome may be attributable to TOFA’s unique dual action, simultaneously modulating lipid synthesis and actively promoting energy metabolism.
Justin Y. Lee, the study’s lead author and a postdoctoral scholar at UCSF who conducted the research as a doctoral candidate at Berkeley, emphasized the coordinated nature of TOFA’s metabolic effects. He stated that the compound does not merely inhibit lipid synthesis; rather, it orchestrates a broader metabolic response by activating pathways that enhance energy expenditure. This integrated action, he suggests, may equip the body with a more robust mechanism for handling excess lipid and glucose.
To further elucidate the importance of TOFA’s integrated mechanism, the researchers conducted a comparative study. They investigated whether the observed benefits could be replicated by administering two separate compounds: one designed to suppress lipid production and another intended to stimulate energy expenditure. The results indicated that this combined therapeutic approach failed to achieve the same level of overall metabolic improvement as TOFA administered as a single agent. This finding underscores the hypothesis that TOFA’s unique combination of biological activities is paramount to its efficacy.
Building upon this, the team explored the potential synergy between TOFA and established GLP-1 receptor agonist medications. They investigated the effects of co-administering TOFA with semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in their animal models. The outcomes were highly encouraging: the combination therapies yielded more substantial improvements in body weight, glycemic control, insulin levels, and triglyceride profiles than either treatment administered in isolation.
Professor Nørgaard characterized the relationship between TOFA and GLP-1 drugs as complementary rather than substitutive. He noted that in their experimental settings, TOFA demonstrated additive or even synergistic effects when paired with the appetite-suppressing GLP-1 medications, suggesting a promising avenue for enhanced therapeutic strategies.
Despite the compelling preclinical data, the researchers are quick to emphasize that TOFA’s potential in human therapeutics remains to be rigorously evaluated. Its safety and efficacy in humans are currently unknown and will necessitate comprehensive clinical trials. To facilitate the transition from laboratory research to potential patient application, the researchers have leveraged Berkeley’s robust life sciences entrepreneurship infrastructure, including initiatives like Nucleate and Berkeley SkyDeck. This support has been instrumental in the formation of a company named ReRx Therapeutics, which aims to advance TOFA’s development towards clinical use.
The research was primarily funded through discretionary resources allocated by UC Berkeley, with additional support provided by the UCSF Liver Center and the University of Michigan Animal Phenotyping Core. A comprehensive list of contributing authors includes Chi Zhu, Melissa A. Boldridge, Rachelle L. Stark, Lei Xu, Federico Gonzalez, Xin Tang, Kaitlyn T. Dang, and Kook Son from UC Berkeley; Gracia Bonilla, Kashish Chetal, and Ruslan I. Sadreyev from Massachusetts General Hospital; Kosuke Watari and Michael Karin from the University of California, San Diego; Christina Papa and Bilal N. Sheikh from the Helmholtz Center Munich; and Prabha Ibrahim from ReRx Therapeutics.
About the Author
